MedPath
Found 439 clinical trials|View Analysis
Sort by:

Effects of Intranasal Oxytocin in the Treatment of Benzodiazepine Withdrawal: A Pilot RCT

Phase 2
Recruiting
Conditions
Benzodiazepine Dependence
Interventions
Drug: Saline (NaCl 0,9 %) (placebo)
Drug: Oxytocin nasal spray
First Posted Date
2025-01-03
Last Posted Date
2025-01-03
Lead Sponsor
St. Olavs Hospital
Target Recruit Count
60
Registration Number
NCT06757517
Locations
🇳🇴

Blue Cross, Clinic Lade, Trondheim, Trøndelag, Norway

Study on the Improvement of Microcirculation in Patients With Sepsis by Vitamin B6, Vitamin B12 and Vitamin C

Not Applicable
Recruiting
Conditions
Septic Shock
Interventions
Drug: vitamin B6+ Vitamin B12 +vitamin C
Drug: vitamin B6+ Vitamin B12
Drug: vitamin C
Drug: 0.9%Nacl
First Posted Date
2024-12-27
Last Posted Date
2025-01-07
Lead Sponsor
Fan Zeng
Target Recruit Count
296
Registration Number
NCT06749756
Locations
🇨🇳

Sichuan Provincial People's Hospital, Chengdu, Sichuan, China

Role of Ondansetron in Spinal Anaesthesia Induced Hypotension

Phase 2
Not yet recruiting
Conditions
Spinal Anaesthesia Induced Hypotension
Interventions
Drug: Ondansetron (Zofran)
Drug: Saline (NaCl 0,9 %) (placebo)
First Posted Date
2024-12-10
Last Posted Date
2024-12-10
Lead Sponsor
Assiut University
Target Recruit Count
160
Registration Number
NCT06727201
Locations
🇪🇬

Assiut university, Assiut, Egypt

Vaginal Cuff Anesthesia and Post-Operative Pain Medication Use

Phase 4
Recruiting
Conditions
Hysterectomy
Post Operative Analgesia
Interventions
Drug: Bupivacain
Other: Saline (NaCl 0,9 %) (placebo)
First Posted Date
2024-12-05
Last Posted Date
2025-01-07
Lead Sponsor
MediSys Health Network
Target Recruit Count
100
Registration Number
NCT06719180
Locations
🇺🇸

Flushing Hospital Medical Center, Flushing, New York, United States

A Phase I Study to Evaluate the Safety and Drug Allergy of Hyaluronidase in Healthy Volunteers

Phase 1
Not yet recruiting
Conditions
Healthy
Interventions
Drug: HLB3-002
Drug: 0.9% NaCl
First Posted Date
2024-12-03
Last Posted Date
2024-12-03
Lead Sponsor
Huons Co., Ltd.
Target Recruit Count
243
Registration Number
NCT06713317
Locations
🇰🇷

Seoul National University Hospital, Seoul, Korea, Republic of

Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and Recombinant Influenza Vaccine in Adult Participants 50 Years of Age and Older

Phase 1
Recruiting
Conditions
COVID-19 Immunization
Influenza Immunization
Interventions
Biological: RIV + rC19 (dose 4)
Biological: RIV (recombinant influenza vaccine)
Biological: rC19 (dose 1)
Biological: RIV + rC19 (dose 1)
Biological: RIV + rC19 (dose 2)
Biological: RIV + rC19 (dose 3)
Other: Placebo (0.9% NaCl)
First Posted Date
2024-11-19
Last Posted Date
2024-12-11
Lead Sponsor
Sanofi
Target Recruit Count
980
Registration Number
NCT06695130
Locations
🇺🇸

Synexus Clinical Research US, Inc. - Cerritos- Site Number : 8400002, Cerritos, California, United States

🇺🇸

Central Phoenix Medical Clinic- Site Number : 8400009, Phoenix, Arizona, United States

🇺🇸

Synexus Clinical Research US - Vista- Site Number : 8400010, Vista, California, United States

and more 9 locations

Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and High-Dose Inactivated Influenza Vaccine in Adult Participants 50 Years of Age and Older

Phase 1
Recruiting
Conditions
COVID-19 Immunization
Influenza Immunization
Interventions
Biological: IIV-HD + rC19 (dose 3)
Biological: IIV-HD + rC19 (dose 4)
Biological: IIV-HD
Biological: rC19 (dose 1)
Biological: IIV-HD + rC19 (dose 1)
Biological: IIV-HD + rC19 (dose 2)
Other: Placebo (0.9% NaCl)
First Posted Date
2024-11-19
Last Posted Date
2024-12-04
Lead Sponsor
Sanofi
Target Recruit Count
980
Registration Number
NCT06695117
Locations
🇺🇸

Simon Williamson Clinic - Birmingham- Site Number : 8400003, Birmingham, Alabama, United States

🇺🇸

AES - DRS - Optimal Research Alabama - Huntsville Site Number : 8400006, Huntsville, Alabama, United States

🇺🇸

Orange Grove Family Practice- Site Number : 8400012, Tucson, Arizona, United States

and more 9 locations

Effects of IL-1 Beta Inhibition on Vascular Inflammation in TET2 Clonal Hematopoiesis

Phase 2
Not yet recruiting
Conditions
Vascular Inflammation
ASCVD
ASCVD Management
Interventions
Drug: CANAKINUMAB (ILARIS®)
Drug: Saline (NaCl 0,9 %) (placebo)
First Posted Date
2024-11-15
Last Posted Date
2024-11-18
Lead Sponsor
Massachusetts General Hospital
Target Recruit Count
120
Registration Number
NCT06691217
Locations
🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

Ephedrine for Reducing Onset Time of Rocurinium in Elderly Patients

Phase 4
Not yet recruiting
Conditions
Neuromuscular Blockade
Interventions
Drug: Ephedrine Hydrochloride 30 mg/ml
Drug: Saline (NaCl 0,9 %) (placebo)
First Posted Date
2024-11-08
Last Posted Date
2024-11-08
Lead Sponsor
Matias Vested
Target Recruit Count
80
Registration Number
NCT06681662
Locations
🇩🇰

Department of Anaesthesiology, Pain and Respiratory Support, Rigshospitalet Glostrup, Copenhagen, Denmark

🇩🇰

Department of Anesthesia, Centre of Head and Orthopedics, 6013 Rigshospitalet, Copenhagen, Denmark

Comparison Between Botox and Magnesium Sulfate Effect in Treatment of Myofascial Pain Trigger Points Within the Masseter Muscle

Phase 2
Not yet recruiting
Conditions
Myofacial Pain
Trigger Points, Myofascial
Interventions
Drug: MgSO4
Drug: BOTOX-A
Drug: Saline (NaCl 0,9 %) (placebo)
First Posted Date
2024-11-06
Last Posted Date
2024-11-11
Lead Sponsor
Misr University for Science and Technology
Target Recruit Count
60
Registration Number
NCT06676475
Locations
🇪🇬

Misr university for science and technology, GIza, Egypt

© Copyright 2025. All Rights Reserved by MedPath